Jaguar Gene Therapy

Jaguar Gene Therapy, LLC is a Deerfield portfolio company targeting serious disorders with high unmet medical need caused by single-gene defects and will leverage AAV as a delivery platform to develop treatments The Company has a skilled senior leadership team led by former executives from AveXis which will guide the development of the gene therapy programs, with capabilities including manufacturing and supply chain, regulatory, clinical/medical, finance and search and evaluation. Deerfield funded the Company with a Preferred Series A to execute on its first four programs.